{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:26:56Z","timestamp":1786987616395,"version":"build-2736575974"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ctrv.2020.102063","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T03:13:35Z","timestamp":1592882015000},"page":"102063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines)"],"prefix":"10.1016","volume":"88","author":[{"given":"Florian","family":"Slimano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Baudouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Zerbit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Toulemonde-Deldicque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Thomas-Schoemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gine","family":"Chevrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika\u00ebl","family":"Daouphars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Madelaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Pourroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Tournamille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Astier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Ranchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Cazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Rioufol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7798","key":"10.1016\/j.ctrv.2020.102063_b0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ctrv.2020.102063_b0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102063_b0015","unstructured":"World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Available from: https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 [accessed April, 5th 2020]."},{"issue":"10","key":"10.1016\/j.ctrv.2020.102063_b0020","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.bbmt.2005.07.007","article-title":"Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies","volume":"11","author":"Martino","year":"2005","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"18","key":"10.1016\/j.ctrv.2020.102063_b0025","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1002\/cncr.27447","article-title":"A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries: early therapy improves outcomes","volume":"118","author":"Chemaly","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2020.102063_b0030","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1086\/425004","article-title":"Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy","volume":"39","author":"Nichols","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ctrv.2020.102063_b0035","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1086\/597089","article-title":"Infectious complications of antilymphocyte therapies in solid organ transplantation","volume":"48","author":"Issa","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ctrv.2020.102063_b0040","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102063_b0045","first-page":"CD008983","article-title":"Influenza vaccines in immunosuppressed adults with cancer","volume":"2","author":"Bitterman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102063_b0050","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/23744235.2019.1592217","article-title":"High mortality from viral pneumonia in patients with cancer","volume":"51","author":"Kim","year":"2019","journal-title":"Infect Dis"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102063_b0055","doi-asserted-by":"crossref","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","article-title":"Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis","volume":"55","author":"Guan","year":"2020","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102063_b0060","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","article-title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China","volume":"31","author":"Zhang","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102063_b0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.0980","article-title":"SARS-CoV-2 Transmission in patients with cancer at a tertiary care hospital in Wuhan, China","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"issue":"368","key":"10.1016\/j.ctrv.2020.102063_b0070","doi-asserted-by":"crossref","first-page":"m1174","DOI":"10.1136\/bmj.m1174","article-title":"Covid-19 and long term conditions: what if you have cancer, diabetes, or chronic kidney disease?","volume":"25","author":"Extance","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2020.102063_b0075","unstructured":"French High Council for Public Health, Provisional statement: Recommendations on prevention and management of Covid-19 in patients at risk of severe forms. Rapport de l\u2019HCSP. Paris: Haut Conseil de la Sant\u00e9 Publique; 2020 Mar. Available from: https:\/\/www.hcsp.fr\/explore.cgi\/avisrapportsdomaine?clefr=799 [accessed April, 23th 2020]."},{"key":"10.1016\/j.ctrv.2020.102063_b0080","doi-asserted-by":"crossref","unstructured":"Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA; 2020 [in press]. https:\/\/doi.org\/10.1001\/jama.2020.4683.","DOI":"10.1001\/jama.2020.4683"},{"issue":"13","key":"10.1016\/j.ctrv.2020.102063_b0085","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S1470-2045(11)70040-7","article-title":"Polypharmacy in elderly patients with cancer: clinical implications and management","volume":"12","author":"Lees","year":"2011","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2020.102063_b0090","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/jgs.12942","article-title":"Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment","volume":"62","author":"Maggiore","year":"2014","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.ctrv.2020.102063_b0095","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/S1470-2045(20)30149-2","article-title":"Risk of COVID-19 for patients with cancer","volume":"21","author":"Wang","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102063_b0100","doi-asserted-by":"crossref","DOI":"10.1177\/1534735420912811","article-title":"Challenges and countermeasures of integrative cancer therapy in the epidemic of COVID-19","volume":"19","author":"Yang","year":"2020","journal-title":"Integr Cancer Ther"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102063_b0105","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.annonc.2020.03.286","article-title":"Managing COVID-19 in the oncology clinic and avoiding the distraction effect","volume":"31","author":"Cortiula","year":"2020","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102063_b0110","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/bjs.11627","article-title":"COVID-19 pandemic: perspectives on an unfolding crisis","volume":"107","author":"Spinelli","year":"2020","journal-title":"Br J Surg"},{"issue":"3S1","key":"10.1016\/j.ctrv.2020.102063_b0115","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.jviscsurg.2020.03.008","article-title":"Strategy for the practice of digestive and oncological surgery during the Covid-19 epidemic","volume":"157","author":"Tuech","year":"2020","journal-title":"J Visc Surg"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102063_b0120","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(20)30204-7","article-title":"The official French guidelines to protect patients with cancer against SARS-CoV-2 infection","volume":"21","author":"You","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102063_b0125","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(20)30217-5","article-title":"Cancer guidelines during the COVID-19 pandemic","volume":"21","author":"Burki","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2020.102063_b0130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1470-2045(09)70069-5","article-title":"Nosocomial infections in patients with cancer","volume":"10","author":"Kamboj","year":"2009","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2020.102063_b0135","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/SLA.0000000000001484","article-title":"Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways","volume":"264","author":"Longbottom","year":"2016","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.ctrv.2020.102063_b0140","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102063_b0145","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41571-020-0394-y","article-title":"COVID-19 and cancer: do we really know what we think we know?","volume":"17","author":"Robinson","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102063_b0150","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-20-0516","article-title":"Fatality rate of cancer patients with COVID-19 in a New York hospital system","author":"Mehta","year":"2020","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102063_b0155","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41571-020-0362-6","article-title":"Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic","volume":"17","author":"Hanna","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2020.102063_b0160","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1001\/jama.2011.749","article-title":"Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review of meta-analysis","volume":"305","author":"Biagi","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102063_b0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-016-3960-3","article-title":"The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis","volume":"160","author":"Raphael","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"10.1016\/j.ctrv.2020.102063_b0170","first-page":"1469","article-title":"Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized open-label, international duration evaluation of adjuvant (IDEA) France","volume":"36","author":"Andr\u00e9","year":"2018","journal-title":"Phase III Trial J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2020.102063_b0175","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.dld.2020.03.031","article-title":"COVID-19 epidemic: proposed alternatives in the management of digestive cancers: a French Intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)","volume":"52","author":"Di Fiore","year":"2020","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ctrv.2020.102063_b0180","doi-asserted-by":"crossref","unstructured":"Grellety T, Ravaud A, Canivet A, Ganem G, Giraud P, Guimbaud R, et al. [SARS-CoV-2\/COVID 19 infection and solid cancers: synthesis of recommendations for health professionals]. Bull Cancer; 2020 [in press]. https:\/\/doi.org\/10.1016\/j.bulcan.2020.03.001.","DOI":"10.1016\/j.bulcan.2020.03.001"},{"key":"10.1016\/j.ctrv.2020.102063_b0185","first-page":"1","article-title":"The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donrs, and patients undergoing CAR T-cell therapy","volume":"13","author":"Ljungman","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2020.102063_b0190","unstructured":"European Centre for Disease Prevention and Control. Coronavirus disease 2019 (COVID-19) and supply of substances of human origin in the EU\/EEA [Internet]. European Centre for Disease Prevention and Control. 2020 Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/coronavirus-disease-2019-covid-19-and-supply-substances-human-origin-eueea [accessed April, 23th 2020]."},{"key":"10.1016\/j.ctrv.2020.102063_b0195","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.26050","article-title":"Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis","author":"Tian","year":"2020","journal-title":"J Med Virol"},{"issue":"10","key":"10.1016\/j.ctrv.2020.102063_b0200","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1111\/bcp.13933","article-title":"Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: a network meta-analysis","volume":"85","author":"Fachi","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102063_b0205","first-page":"1119","article-title":"Treatment guidance for lung cancer patients during the COVID-19 pandemic","volume":"15","author":"Dingerman","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102063_b0210","first-page":"CD-20-0596","article-title":"Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers","author":"Luo","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2020.102063_b0215","doi-asserted-by":"crossref","DOI":"10.2217\/imt-2020-0067","article-title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors","author":"Bersanelli","year":"2020","journal-title":"Immunotherapy"},{"issue":"11","key":"10.1016\/j.ctrv.2020.102063_b0220","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40264-016-0450-9","article-title":"Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas","volume":"39","author":"Shah","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.ctrv.2020.102063_b0225","article-title":"Proposals for managing patients with thoracic malignancies during COVID-19 pandemic","author":"Girard","year":"2020","journal-title":"Respir Med Res"},{"issue":"11","key":"10.1016\/j.ctrv.2020.102063_b0230","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/annonc\/mdy408","article-title":"Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer","volume":"29","author":"Long","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102063_b0235","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","article-title":"A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","volume":"131","author":"Lala","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102063_b0240","unstructured":"European Society for Medical Oncology. ESMO management and treatment adapted recommendations in the COVID-19 era: lung cancer. Available from: https:\/\/www.esmo.org\/guidelines\/cancer-patient-management-during-the-covid-19-pandemic\/lung-cancer-in-the-covid-19-era [accessed April, 26th 2020]."},{"key":"10.1016\/j.ctrv.2020.102063_b0245","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","article-title":"Efficacy and safety of first-line carboplatine-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis","volume":"135","author":"Griesinger","year":"2019","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2020.102063_b0250","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102063_b0255","doi-asserted-by":"crossref","DOI":"10.1200\/OP.20.00286","article-title":"Management of lung cancer during the COVID-19 pandemic","author":"Singh","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"14","key":"10.1016\/j.ctrv.2020.102063_b0260","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","article-title":"Chemotherapy in fisrt-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data","volume":"30","author":"Rossi","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102063_b0265","unstructured":"European Society for Medical Oncology. ESMO management and treatment adapted recommendations in the COVID-19 era: Melanoma. Available from: https:\/\/www.esmo.org\/guidelines\/cancer-patient-management-during-the-covid-19-pandemic\/melanoma-in-the-covid-19-era [accessed April, 26th 2020]."},{"issue":"5","key":"10.1016\/j.ctrv.2020.102063_b0270","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.purol.2020.03.009","article-title":"Recommendations CCAFU on the management of cancers of the urogenital system during an epidemic with Coronavirus COVID-19","volume":"30","author":"M\u00e9jean","year":"2020","journal-title":"Prog Urol"},{"issue":"4","key":"10.1016\/j.ctrv.2020.102063_b0275","first-page":"395","article-title":"les membres du bureau du Groupe d\u2019\u00e9tude des tumeurs uro-g\u00e9nitales. Therapeutic options for genitourinary cancers during the epidemic period of COVID-19","volume":"107","author":"Fizazi pour","year":"2020","journal-title":"Bull Cancer"},{"key":"10.1016\/j.ctrv.2020.102063_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.04.479","article-title":"Androgene-deprivation therapies for prostate cancer and risk of infection by SARS-CoV- 2: a population-based study (n=4532)","author":"Montopoli","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102063_b0285","unstructured":"European Society for Medical Oncology. ESMO management and treatment adapted recommendations in the COVID-19 era: Colorectal cancer (CRC). Available from: https:\/\/www.esmo.org\/guidelines\/cancer-patient-management-during-the-covid-19-pandemic\/gastrointestinal-cancers-colorectal-cancer-crc-in-the-covid-19-era [accessed April, 26th 2020]."},{"issue":"8","key":"10.1016\/j.ctrv.2020.102063_b0290","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/MPA.0b013e31829e2006","article-title":"Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adecnocarcinoma","volume":"42","author":"Mahaseth","year":"2013","journal-title":"Pancreas"},{"issue":"25","key":"10.1016\/j.ctrv.2020.102063_b0295","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"10184","key":"10.1016\/j.ctrv.2020.102063_b0300","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2020.102063_b0305","unstructured":"European Society for Medical Oncology. ESMO management and treatment adapted recommendations in the COVID-19 era: Gastro-oesophageal tumours. Available from: https:\/\/www.esmo.org\/guidelines\/cancer-patient-management-during-the-covid-19-pandemic\/gastrointestinal-cancers-gastro-oesophageal-tumours-in-the-covid-19-era [accessed April, 26th 2020]."},{"issue":"Suppl 3","key":"10.1016\/j.ctrv.2020.102063_b0310","article-title":"ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer","volume":"5","author":"de Azambuja","year":"2020","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102063_b0315","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.bulcan.2020.03.008","volume":"107","author":"Gligorov","year":"2020","journal-title":"Bull Cancer"},{"key":"10.1016\/j.ctrv.2020.102063_b0320","unstructured":"French Society of Otolaryngology and Head-and-Neck Surgery. Available from: https:\/\/ressources-aura.fr\/wp-content\/uploads\/2020\/04\/covid-19-et-orl-propositions-onco-UNICANCER-_26-03-2020-1.pdf [accessed April, 26th 2020]."},{"key":"10.1016\/j.ctrv.2020.102063_b0325","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaa090","article-title":"Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic","author":"Mohile","year":"2020","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.ctrv.2020.102063_b0330","unstructured":"European Society for Medical Oncology. ESMO management and treatment adapted recommendations in the COVID-19 era: Primary brain tumor. Available from: https:\/\/www.esmo.org\/guidelines\/cancer-patient-management-during-the-covid-19-pandemic\/primary-brain-tumours-in-the-covid-19-era [accessed 20 May 2020]."},{"key":"10.1016\/j.ctrv.2020.102063_b0335","unstructured":"American Society of Hematology. COVID-19 and Indolent Lymphomas - Hematology.org. Available from: https:\/\/www.hematology.org:443\/covid-19\/covid-19-and-indolent-lymphomas [accessed April, 26th 2020]."},{"key":"10.1016\/j.ctrv.2020.102063_b0340","unstructured":"European Society for Medical Oncology. ESMO management and treatment adapted recommendations in the COVID-19 era: Indolent B-NHL (Follicular Lymphoma, Marginal Zone Lymphoma, Waldenstr\u00f6m\u2019s Macroglobulinaemia). Available from: https:\/\/www.esmo.org\/guidelines\/cancer-patient-management-during-the-covid-19-pandemic\/haematological-malignancies-indolent-b-nhl-in-the-covid-19-era [accessed April, 26th 2020]."},{"key":"10.1016\/j.ctrv.2020.102063_b0345","unstructured":"European Society for Medical Oncology. ESMO management and treatment adapted recommendations in the COVID-19 era: Diffuse large B-cell lymphoma, Mantle cell lymphoma and Aggressive T-cell lymphomas. Available from: https:\/\/www.esmo.org\/guidelines\/cancer-patient-management-during-the-covid-19-pandemic\/haematological-malignancies-dlbcl-mcl-and-aggressive-t-cell-lymphoma-in-the-covid-19-era [accessed April, 26th 2020]."},{"key":"10.1016\/j.ctrv.2020.102063_b0350","unstructured":"American Society of Hematology. COVID-19 and CLL \u2013 Hematology.org. Available from: https:\/\/www.hematology.org:443\/covid-19\/covid-19-and-cll [accessed April, 26th 2020]."},{"key":"10.1016\/j.ctrv.2020.102063_b0355","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019H\u00e9matologie (SFH). COVID-19 et prise en charge des maladies d\u2019h\u00e9matologie. Available from: https:\/\/sfh.hematologie.net\/sites\/sfh.hematologie.net\/files\/medias\/documents\/covid-19_propostion_sfh_17-03-2020_0.pdf [accessed April, 26th 2020]."},{"key":"10.1016\/j.ctrv.2020.102063_b0360","unstructured":"Francophone Myeloma Intergroup. Recommandations IFM. Available from: https:\/\/www.myelome.fr\/PressRoom\/50\/2020-03-25-Flash-info-COVID-19.html [accessed April, 26th 2020]."},{"key":"10.1016\/j.ctrv.2020.102063_b0365","doi-asserted-by":"crossref","DOI":"10.1159\/000507690","article-title":"Multiple myeloma in the time of COVID-19","author":"Al Saleh","year":"2020","journal-title":"Acta Haematol"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102063_b0370","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/s41375-019-0384-1","article-title":"Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance","volume":"33","author":"Kumar","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102063_b0375","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102063_b0380","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1286","article-title":"Potential effects of coronaviruses on the cardiovascular system: a review","author":"Madjid","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10.1016\/j.ctrv.2020.102063_b0385","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and efficacu of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"Suppl. 5","key":"10.1016\/j.ctrv.2020.102063_b0390","doi-asserted-by":"crossref","first-page":"v461","DOI":"10.1093\/annonc\/mdx380.002","article-title":"1297O \u2013 Randomized results of fixed-duraction (1-yr) vs continuous nivolumab in patients with advanced non-small cell lung cancer","volume":"28","author":"Spigel","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2020.102063_b0395","first-page":"LMT18","article-title":"Immune checkpoint inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions? Lung Cancer","volume":"8","author":"Metro","year":"2020","journal-title":"Manage"},{"issue":"368","key":"10.1016\/j.ctrv.2020.102063_b0400","doi-asserted-by":"crossref","first-page":"m1185","DOI":"10.1136\/bmj.m1185","article-title":"Non-steroidal anti-inflammatory drugs and covid-19","volume":"27","author":"Little","year":"2020","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.ctrv.2020.102063_b0405","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102063_b0410","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41591-020-0874-8","article-title":"Caring for patients with cancer in the COVID-19 era","volume":"26","author":"van de Haar","year":"2020","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ctrv.2020.102063_b0415","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/clpt.2009.214","article-title":"Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval)","volume":"87","author":"Morganroth","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2020.102063_b0420","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ijcard.2016.09.046","article-title":"Management and research in cancer treatment-related cardiovascular toxicity: challenges and perspectives","volume":"224","author":"Cautela","year":"2016","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.ctrv.2020.102063_b0425","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10549-013-2585-z","article-title":"Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen","volume":"139","author":"Binkhorst","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.ctrv.2020.102063_b0430","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/annonc\/mdw100","article-title":"Ocular toxicities of MEK inhibitors and other targeted therapies","volume":"27","author":"Stjepanovic","year":"2016","journal-title":"Ann Oncol"},{"issue":"10236","key":"10.1016\/j.ctrv.2020.102063_b0435","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID- 19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ctrv.2020.102063_b0440","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ctrv.2020.102063_b0445","doi-asserted-by":"crossref","DOI":"10.1200\/OP.20.00295","article-title":"Providing oncology pharmacy services during the coronavirus pandemic: french society for oncology pharmacy (Soci\u00e9t\u00e9 Francaise de Pharmacie Oncologique-SFPO) guidelines","author":"Pourroy","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ctrv.2020.102063_b0450","article-title":"Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic","author":"Brown","year":"2020","journal-title":"Res Soc Adm Pharm"},{"key":"10.1016\/j.ctrv.2020.102063_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104776","article-title":"The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good","author":"Gray","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ctrv.2020.102063_b0460","unstructured":"Grenoble University. Hedrine\u00a0: Herb Drug Interaction Database. Available from: https:\/\/hedrine.univ-grenoble-alpes.fr\/ [accessed April, 23th 2020]."},{"key":"10.1016\/j.ctrv.2020.102063_b0465","unstructured":"Memorial Sloan Kettering Cancer Center. About Herbs, Botanicals & Other Products. Available from: https:\/\/www.mskcc.org\/cancer-care\/diagnosis-treatment\/symptom-management\/integrative-medicine\/herbs [accessed April, 23th 2020]."},{"issue":"5","key":"10.1016\/j.ctrv.2020.102063_b0470","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S1470-2045(20)30226-6","article-title":"Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic","volume":"21","author":"de Paula","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102063_b0475","unstructured":"Solidarity 2019 coronavirus drug clinical trial. Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov\/solidarity-clinical-trial-for-covid-19-treatments [accessed April, 10th 2020]."},{"issue":"5","key":"10.1016\/j.ctrv.2020.102063_b0480","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/sctm.18-0230","article-title":"A phase I study to assess the safety and cancer-homing ability of allogeneic bone marrow-derived mesenchymal stem cells in men with localized prostate cancer","volume":"8","author":"Schweizer","year":"2019","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.ctrv.2020.102063_b0485","unstructured":"Electronic Medicines Compendium. Avloclor 250 mg tablets. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/2272 [accessed May, 25th 2020]."},{"issue":"6","key":"10.1016\/j.ctrv.2020.102063_b0490","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2125.2000.00197.x","article-title":"Influence of hydroxychloroquine on the bioavailability of oral metoprolol","volume":"49","author":"Somer","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2020.102063_b0495","unstructured":"Electronic Medicines Compendium. Colchicine 500 \u00b5g tablets. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/6415\/smpc [accessed May, 25th 2020]."},{"key":"10.1016\/j.ctrv.2020.102063_b0500","unstructured":"European Medicines Agency. Jakavi\u2013European Public Assessment Report; 2020. Available from: https:\/\/www.jakavi.com\/globalassets\/assets1\/emea-combined-h-2464-en.pdf [accessed May, 25th 2020]."},{"key":"10.1016\/j.ctrv.2020.102063_b0505","unstructured":"European Medicines Agency. RoActemra\u2013European Public Assessment Report; 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roactemra-epar-product-information_fr.pdf [accessed May, 25th 2020]."},{"issue":"8","key":"10.1016\/j.ctrv.2020.102063_b0510","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102063_b0515","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.annonc.2020.03.300","article-title":"Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report","volume":"31","author":"Michot","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102063_b0520","unstructured":"French national drug safety agency. COVID-19 \u2013 Clinical Trials underway. Available from: https:\/\/www.ansm.sante.fr\/Activites\/Essais-cliniques\/COVID-19-Essais-cliniques-en-cours\/(offset)\/0 [accessed April, 6th 2020]."},{"issue":"11","key":"10.1016\/j.ctrv.2020.102063_b0525","doi-asserted-by":"crossref","first-page":"756","DOI":"10.7326\/M20-1133","article-title":"A war on two fronts: cancer care in the time of COVID-19","volume":"172","author":"Kutikov","year":"2020","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.ctrv.2020.102063_b0530","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.critrevonc.2014.12.014","article-title":"Concomitant drugs with low risks of drug-drug interactions for use in oncology clinical trials","volume":"94","author":"Ranchon","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2020.102063_b0535","unstructured":"French national drug safety agency. COVID-19 \u2013 Clinical Trials underways \u2013 What is the recommended pathway in case of home medicines delivery? Available from: https:\/\/www.ansm.sante.fr\/Activites\/Essais-cliniques\/COVID-19-Essais-cliniques-en-cours\/COVID-19-Essais-cliniques-en-cours-Quel-est-le-circuit-preconise-en-cas-de-delivrance-a-domicile [accessed April, 10th 2020]."},{"issue":"5","key":"10.1016\/j.ctrv.2020.102063_b0540","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/ijgc-2020-001419","article-title":"COVID-19 global pandemic: options for management of gynecologic cancers","volume":"30","author":"Ramirez","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102063_b0545","first-page":"561","article-title":"Fighting against COVID- 19: innovative strategies for clinical pharmacists","volume":"30","author":"Li","year":"2020","journal-title":"Res Soc Adm Pharm"},{"issue":"8","key":"10.1016\/j.ctrv.2020.102063_b0550","first-page":"3557","article-title":"Clinical and economic impact of medication reconciliation in cancer patients: a systematic review","volume":"28","author":"Herledan","year":"2020","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2020.102063_b0555","article-title":"Pharmaceutical consultations in oncology: French Society for Oncology Pharmacy (Soci\u00e9t\u00e9 Francaise de Pharmacie Oncologique \u2013 SFPO) guidelines","volume":"2","author":"Petit-Jean","year":"2019","journal-title":"Eur J Oncol Pharm"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102063_b0560","first-page":"45","article-title":"Apports des consultations pharmaceutiques dans la prise en charge des anticanc\u00e9reux oraux","volume":"4","author":"Chevrier","year":"2018","journal-title":"Innov Ther Oncol"},{"key":"10.1016\/j.ctrv.2020.102063_b0565","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/jac5.1231","article-title":"Roles of the clinical pharmacist during the COVID-19 pandemic","volume":"3","author":"Gross","year":"2020","journal-title":"J Am Coll Clin Pharm"},{"key":"10.1016\/j.ctrv.2020.102063_b0570","unstructured":"International Pharmaceutical Federation. FIP Covid-19 Information Hub - FIP. Available from: https:\/\/www.fip.org\/coronavirus [accessed April, 23th 2020]."},{"key":"10.1016\/j.ctrv.2020.102063_b0575","unstructured":"Guidelines for tumor board meetings in the context of Covid-19. Available from: https:\/\/www.e-cancer.fr\/Professionnels-de-sante\/Coronavirus-COVID-19\/Conseils-sur-l-organisation-des-reunions-de-concertation-pluridisciplinaire-RCP-en-cancerologie-dans-le-contexte-de-l-epidemie-au-Covid-19 [accessed April, 6th 2020]."},{"issue":"5","key":"10.1016\/j.ctrv.2020.102063_b0580","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jaip.2020.03.008","article-title":"Telemedicine in the Era of COVID-19","volume":"8","author":"Portnoy","year":"2020","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220301018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220301018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:25:17Z","timestamp":1759656317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220301018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":116,"alternative-id":["S0305737220301018"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102063","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines)","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102063"}}